Social Capital Suvretta Holdings Corp I
Social Capital Suvretta Holdings Corp I — Akili — SPAC Merger (August 2022)
43 slides from Social Capital Suvretta Holdings Corp I's SPAC merger presentation, Aug 25, 2022
Slide 1: AUG 2022
AUG 2022
Slide 2: About this presentation
About this presentation This investor presentation (“Presentation”) contains proprietary and confidential information of Social Capital Suvretta Holdings Corp. I (“SCS”) and Akili Interactive Labs, Inc. (“Akili” or the “Company”), and the entire content should be considered “Confidential Information
Slide 3: About this presentation: Forward Looking Statements
About this presentation FORWARD LOOKING STATEMENTS Certain statements, estimates, targets and projections in this investor presentation may be considered forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 199
Slide 4: Establishing a new era of cognitive medicine through game-changing technologies
Establishing a new era of cognitive medicine through game-changing technologies Establishing a new era of congnitive medicine through game-chaning technologies
Slide 5: Management team
EDDIE MARTUCCI, PHD Chief Executive Officer, Co-Founder Former: PureTech Health MATT FRANKLIN President, Chief Operating Officer Former: Exact Sciences, Foundation Medicine, Boston Scientific JON DAVID Chief Product Officer Former: Microsoft, EA, Glu ANIL JINA, MD Chief Medical Officer Former: Pfize
Slide 6: Brain function is the next frontier
Brain function is the next frontier
Slide 7: Akili milestones timeline 2013-2022
2013 2016 2018 2020 2020 2022 0 0 0 0 0 0 In a landmark decision~ FDA greenlights a video game for kids with ADHD S AT+ I’Rf. 1st PATENT GRANTED FOR AKILI’S UNIQUE DTX MECHANISM Akili and Pfi z Akili study grabs atte t· . zer successfully with d’ · n ron gamlfy Afzheimer’s—0 DEPRESSION RCT IQJtal th
Slide 8: EndeavorRx: first of its kind digital treatment delivered through a video game interface
eavor A First of its kind digital treatment delivered through a video game interface; currently being prescribed by physicians for pediatric patients with ADHD FDA indication: EndeovorRx® is a digital therapeutic indicated to improve attention function as measured by computer-based testing in childr
Slide 9: Current Akili pipeline: initial populations demonstrating potential breadth of technology
Current Akili pipeline: initial populations demonstrating potential breadth of technology 0 RESEARCH POC PIVOTAL COMMERCIAL Pediatric ADHD 8-12 y/o (US) Pediatric ADHD (EU) e e e CE SSME ~ Pediatric ADHD 6-17 y/o (Japan) 0 OG Pediatric ADHD 13-17 y/o (US) Adullt ADHD 18+ y/o (US) en w %—• Early chil
Slide 10: Recognition of cognitive function issues is at an all time high
Recognition of cognitive function issues is at an all time high —--co~ ) experience adverse effects from medication2 up to up to of children have attention deficitsl of adults have cognitive impairments that may result in a decrease in independence and quality of life3 up to number of people with of
Slide 11: Cognitive impairments exist across many medical conditions
Cognitive impairmen~ts exist across many medical conditions I B POLAR DISORDER TRAUMATC 8 R A N VASCULAR DISEASE ~PUS MCI J u R y SCHIZOPHRENIA c E 0 SENSO y PROCESSING DISORD R DYSLEX A HUNTINGTON’S DISEASE C R COY Y COVID BRAI OG 11
Slide 12: Current treatments and approaches are inadequate
Current treatments and approaches are inadequate A new category of medicine Pharmaceuticals Physiologically-active DTx Behavioral therapy • Largely treats • MOA-based efficacy • Can lead to mixed results symptoms • Positive safety profile • Can have accessibility (vs. function) and cost issues • FDA
Slide 13: Science & Product Development
Science & Product Devlopment 13
Slide 14: Akili has set the standard for clinical validation in digital medicine
Akili has set the standard for clinical validation in digital medicine —--co~ TH L T igital Health syc Dig· al Peer-reviewed publications Cognitive dysfunction in ... ATTE TION DEF CIT HYPERACTIVITY DISORDER (ADHD) ALZHEIMER’S DISEASE (AD) AUTISM SPECTRUM DISO DE (ASD) SSMETM DEPRESSION (MOD) TM Sel
Slide 15: SSME is designed to target frontoparietal attention control networks
SSMETM is designed to target frontoparietal attention control networks —--co~ Attention Control: Capacity to apply necessary attention at appropriate time and place, while monitoring environment for new sources of information, to enable optimal processing of task-relevant information. A set of neura
Slide 16: EndeavorRx game mechanics overview
EndeavorRx® game mechanics overview SSME™ NAVIG A TION FOCUS Steer over gates and/or avoid obstacles INTERFERENCE PROCESSING T A R G E T I N G Tap for targets and ignore non-targets MULTITASKING M U LT I T A S K I N G Simultaneous navigation and targeting 16
Slide 17: Effects of SSME on neural signatures of prefrontal attention control
Effects of SSME™on neural signatures of prefrontal attention control —--co Pre-SSME™ Post-SSM E™ Control Healthy older adults: enhanced midline frontal theta (MFT) power and fronta l-posterior theta coherence on EEGl Healthy older adults Healthy younger adults Children with sensory processing dysfun
Slide 18: Core technology advantage: closed-loop system SSME
Core technology advantage: closed-loop system SSME™ 18
Slide 19: Core technology advantage: population-tailored expansion/differentiation
Core technology advantage: population-tailored expansion/diï erentiation Core cognitive engine remains intact, while creating completely unique games tailored for each audience and personalized for each individual All games include the key SSME™ components yet are completely unique games designed fo
Slide 20: EndeavorRx ADHD clinical studies
Endeavor ADHD clinical studies —--co~ clinical trials children conducted with with ADHD Sensory Processing Autism Spectrum ADHD ADHD ADHD Disorder + ADHD Disorder + ADHD AKL-T01 (no meds) AKL-TOl (on meds) AKL-T01 AKL-T01 AKL-T026 Digital Control AKL-TOl (no meds) Healthy Control Healthy Control Dig
Slide 21: ADHD clinical studies
ADHD clinical studies —--co~ THE LAI\CET STARS STUDY ADJUNCT STUDY na11 Digital Health PRIMARY ENDPOINT PRIMARY ENDPOINT Digital Medicine p::0.006 First Treatment Second Treatment 40 Period Period—r:: f- -1 f--—--1 cu 1.0 E • SSME only (n=76) ~ • SSME (both cohorts) ew • SSME+stimulants (n=130) 0. C
Slide 22: EndeavorRx treatment responder rates across studies
EndeavorRxTM treatment of—responder rates across studiesl,2 —--co~ % children moving into normative range in at least one 36% — objective measure of attention % Children with >1-point improvement 48% 50% 68% % Children with ~30% improvement 24% 27% 45% “Do you think playing the app improved your chi
Slide 23: ADHD Market and EndeavorRx Commercial Launch
ADHT Market EndeavoRx Commerical Launch 23
Slide 24: Pediatric ADHD
Pediatric ADHDl % of children with ADHD spend per ADHD child vs. have attention deficits neurotypical child % patients tried/trying/plan to try not currently on or well-non-pharmacological treatments controlled by medication Willcutt (2012) Neurotheropeutics, 9(3): 490-499; additudemag.com/ 24 cost-
Slide 25: EndeavorRx has a large and attractive initial target population
EndeavorRx® has a large and attractive initial target population in addressing attention issues ADHD MARKET3—US ONLY (patients in millions) 11M Current prescription ADHD treatments in the US address large patient populations 4.7M 8M ADULT $ 1 ~ 10Bn 3.3M A D U LT ADHD MARKET 2.8M AG E S 1 3—1 7 1.9M
Slide 26: EndeavorRx: first of its kind digital treatment delivered through a video game
® eavor A First of its kind digital treatment delivered through a video game interface; currently being prescribed by physicians for pediatric patients with ADHD FDA indication: EndeovorRx® is a digital therapeutic indicated to improve attention function as measured by computer-based testing in chil
Slide 27: EndeavorRx Insight companion app for caregivers
Endeavor “””——‘1N SIGHT A • Companion App for Caregivers Tracking Progress Today Provides caregivers with a daily snapshot of their child’s in-game progress. Jul 22 Compliance All Room to missions Caregivers can follow along with their child’s effort and level completion. improve played! Support Car
Slide 28: EndeavorRx distribution model is live
EndeavorRx® distribution model is live —--co~ HCP PRESCRIBES ENDEAVORRX Through PhiiRx to complete IN-PERSON fulfillment VISIT WITH HCP OR TELE-HEALTH VISIT WITH HCP to discuss EndeavorRx as treatment option AKILI ASSIST is committed to supporting caregivers along the journey through our Nurse Navig
Slide 29: Commercialization model
Commercialization model —--co~ Customer-driven model Prescription-therapeutic, hybrid self-pay reimbursement model. Catalyzed by activated consumers (parents unsatisfied with current treatment options) and efficient HCP education and e-prescribing Frictionless Delivery Option for patient doctor or s
Slide 30: EndeavorRx key drivers of the model
EndeavorRx®—key drivers of the model P H A S E PRE-LA UNCH PRE-LA UNCH P R E—L A U N C H PRE-LA UNCH G R O W T H M E T R I C F Y 2 0 2 1 Q 1 ’ 2 2 Q 2 ’ 2 2 V S . Q 2 ’ 2 1 Total Rx Written 1,713 668 772 140% D E M A N D New Rx 1,422 503 602 102% Refill Rx 291 165 170 608% Total Prescribers 877 437
Slide 31: Financial Overview
Financial Overview ARILI
Slide 32: Expected ADHD label expansion
Expected ADHD label expansion INITIAL TARGET POPULATION SIZE2 (patients in millions) ADHD MARKET—US ONLY T O T A L 8 . 1 1 . 1 POC start: H1 ’23 4 3—7 Y E A R—O L D $ 3 . 3 Pivotal data: H2 ’23 E 3 A D U LT U N E V E R 1 . 9 Pivotal data: H2 ’23 2 1 3—1 7 Y E A R—O L D FDA 1 . 8 CLEARED 1 8 – 1 2 Y
Slide 33: $500M+ revenue potential in the US in 5-7 yrs in ADHD alone
$500M+ Revenue potential in the US in 5-7 yrs in ADHD alone $500M+ per yr. US ADHD revenues (estimated in 5-7 yrs) Upside potential: • Additional payor coverage over-time reduces % of $300M $200M self-pay 1.5 Rx refills per patient after 1st Rx • Reduced gross-to-net discounting ~15% gross-to-net di
Slide 34: Current Akili pipeline: estimated timeframe and next milestones
Current Akili pipeline: initial populations demonstrating potential breadth of technology 0 ESTIMATEDl NEXT MILESTONE TIME IFRAME Pediatric ADHD 8-12 y/o (US) Launch H2 ‘22 Pediatric ADHD (EU) Launch —SSMETM Pediatric ADHD 6-17 y/o (Japan) s 10 oo Pivotal trial data H2 ‘23 en Pediatric ADHD 13-17 y/
Slide 35: Thank you
Thank you Contact: Santosh Shabhag sshabhag@akilinteractive.com
Slide 36: Sources supporting slides
Sources supporting slides Disease Area Source of Total Population Source for calculations supporting Initial Target Population ADHD4·7 CDC Survey Estimates, 2014 National Survey on Children’s Health (CDC); 2003-2011 ADHD 8-12 Danielson (2018) J Clin Child Adoles Psychol., 47(2): 199-212 Willcutt (20
Slide 37: Appendix: Clinical Data
APPENDIX Clinical Dota
Slide 38: Autism spectrum disorder (ASD)
Autism spectrum disorder (ASD) 1.3M 410K TOT A L TA R G E T Children with ASD are at high risk for impairments in attention function1 The presence of ADHD symptoms in children with autism spectrum disorder is associated with worse cognitive (attention) control1 Attention impairments contribute to po
Slide 39: Multiple sclerosis (MS)
Multiple sclerosis (MS) PA T I E N T S U S 4 900K 180K TOT A L TA R G E T Incidence of cognitive dysfunction in MS ranges from 20-60%1 7 SSME (n=20) Control (n=20) 6 It is predictive of loss of employment, loss of quality of life, and aïects all aspects of daily life1 5 baseline) clinically meaningf
Slide 40: Major depressive disorder (MDD)
Major depressive disorder (MDD) PA T I E N T S U S 4 19M 2.1M TOT A L TA R G E T Cognitive symptoms are present during up to 94% of 5 SSME (n=37) depressive episodes and up to 44% of periods of 4 Control (n=37) remission1 3 2 Serious impact on patients’ quality of life and activities of ention 1 dai
Slide 41: Acute cognitive dysfunction
Acute cognitive dysfunction PA T I E N T S US 2 81M 700KTBI 1.3MCOVID 1MCHEMO 300KICU TOT A L TA R G E T Cognitive impairments can occur aï…er acute insults to the brain due to trauma, infection, hypoxia, inflammation, medication, toxins, critical illness, cancer etc. 0.4 SSME (n=28) Control (n=28)
Slide 42: Cognitive monitoring
Cognitive monitoring Cognition is oï…en only assessed when there is a specific, subjective complaint from patients, family members, or caregivers1 There is no consistent clinical protocol for how to use cognitive assessment tools1 Most cognitive assessments have not changed in decades and many are s
Slide 43: R&D technologies: beyond SSME
R&D technologies: beyond SSME Priority areas of study: Alzheimers, MCI (mild cognitive impairment) SNAV™ Spatial Navigation Engine S P A T I A L N AV I G A T I O N , E P I S O D I C M E M O R Y BBT ™ Body Brain Trainer AT T E N T I O N , G O A L M A N A G E M E N T , W O R K I N G M E M O R Y 43